Authors
Derya Koç, Miraç Vural Keskinler
Published in
AACE endocrinology and diabetes. Volume 13. Issue 5. Pages 677-678. Epub Apr 18, 2026.
Abstract
Dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists such as tirzepatide are increasingly used for obesity management. These agents delay gastric emptying and may influence the absorption of orally administered drugs, including levothyroxine.
A 48-year-old woman with class I obesity (BMI 32 kg/m2) was diagnosed with overt primary hypothyroidism (TSH 17.1 mIU/L; free T4 0.76 ng/dL). Levothyroxine 25 μg/d achieved biochemical normalization. Tirzepatide 2.5 mg weekly was initiated for weight management. Over 3 months, body weight decreased from 116 kg to 100 kg (-13.8%). Despite confirmed adherence and absence of interacting medications, TSH increased to 20.7 mIU/L with low-normal free T4. Levothyroxine dose was increased to 50 μg/d, resulting in TSH suppression (0.33 mIU/L).
Weight loss is typically associated with reduced levothyroxine requirements; however, this case demonstrated the opposite pattern. Tirzepatide-induced delay in gastric emptying may have impaired levothyroxine absorption. Previous reports with glucagon-like peptide-1 receptor agonists have mainly described reduced levothyroxine requirements, suggesting that this interaction may be variable and patient-specific.
Levothyroxine requirements may increase in some patients following tirzepatide initiation. Clinicians should consider reassessing thyroid function within 6-8 weeks after starting dual incretin therapy.
PMID:
42978782
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 15
- Comments 0